ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
5 hedge funds and large institutions have $677K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 4 closing their positions.
242% more call options, than puts
Call options by funds: $575K | Put options by funds: $168K
34% less capital invested
Capital invested by funds: $1.03M → $677K (-$354K)
38% less funds holding
Funds holding: 8 → 5 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$342K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$425K |
| 2 |
Jane Street
New York
|
-$121K |
| 3 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
-$104K |
| 4 |
GHAM
Gilman Hill Asset Management
New Canaan,
Connecticut
|
-$104K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18.3K |
ZBIO Hedge Fund Activity: Q4 2017 in Review
5 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q4 2017, worth a combined $677K — down 34% from $1.03M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ZBIO and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $342K. The largest seller was Virtu Financial, cutting an estimated $425K.
- 5 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q4 2017, down from 8 in Q3 2017.
- Funds reported $677K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q4 2017, down 34% quarter-over-quarter.
- 1 fund opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q4 2017 and 4 closed out, a net change of -3 holders.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q4 2017 was Susquehanna International Group, an estimated $342K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q4 2017 was Virtu Financial, an estimated $425K sold.
Based on aggregated 13F filings for Q4 2017.